Magstim

New TMS Research: Prevent future pain with pre-emptive, non-invasive brain stimulation. Article states: "Now, in a new study, researchers from the University of New South Wales (UNSW) and Neuroscience Research Australia (NeuRA) have demonstrated that a short course of treatment with TMS before the onset of pain can prevent it from becoming a chronic issue. “Our research showed that repetitive transcranial magnetic stimulation, or rTMS, which is a non-invasive brain stimulation, could be delivered in a preventive way, before pain takes hold,” said Nahian Chowdhury, PhD, a registered psychologist, NeuRA research fellow, lecturer at UNSW and the study’s lead author. #TMS #pain #neuroscience https://lnkd.in/gDrNaaV8

UK TMS NEWS ANNOUNCEMENT   Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved By UKCA for NHS & Private UK Clinics UK System for Patient Treatment of MDD, OCD and Decreasing Anxiety*   Magstim has been awarded UKCA clearance for the Horizon Inspire System, continuing to provide NHS physicians and researchers with next-generation transcranial magnetic stimulation technology to treat patients with MDD, OCD and Decreasing Anxiety*.   “As the first to introduce clinical TMS into the NHS, our team continues delivering innovative treatments to help treat depression and anxiety,” said Professor Alex O’Neill Kerr, MBChB, Medical Director of Transforming Mind Solutions. “This new system takes trusted Magstim TMS technology to the next level, improving patient outcomes.”   Magstim has supplied the NHS with TMS technology for more than 30 years. The Inspire enables both experienced TMS providers as well as those who are new to TMS to get up a running fast to provide patient treatments.”   The Inspire provides high-power air-cooling, ability to deliver back-to-back customizable treatments, all while being easy to use, cost-effective and offering portability between clinic rooms. Magstim TMS technology is cited in more than 20,000 peer reviewed research papers and used in hospitals, clinics and research centers worldwide.   The use of Transcranial Magnetic Stimulation for treating MDD and OCD is increasing worldwide, driven by new studies demonstrating its effectiveness over other treatments (**).   The Horizon Inspire system leverages intuitive preset clinical workflows to simplify the treatment process, delivering precise results with no pulse decay, ensuring the correct dosage. Magstim’s air-cooled coil reduces downtime and eliminates additional cooling expenses. Advanced data analytics tools improve treatment efficacy. * Horizon 3.0 Inspire is indicated for the treatment of MDD in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode, as well as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder (OCD).   ** https://lnkd.in/eK94AXEH Learn more at: https://lnkd.in/gytY6t9w   #TMS #depression #UKCA #NHS

Watch this inspiring NEW TMS VIDEO to learn about Associates in Mental Health & Addiction Services in Winona, Minnesota and their Transcranial Magnetic Stimulation treatments for depression, OCD and anxiety. Here, Dr. Anita Lauria, DNP, FNP-BC, shares insights on #mentalhealth, TMS treatments and how their team improves patient lives. Thank you to Anita Lauria and Dr. Robert Lauria DNP, PMHNP-BC, FNP-BC for your continued passion to help patients improve. #depression #ocd #winona #tms

🎉 We’re thrilled to be at the Royal College of Psychiatrists International Congress 2024! 🎉 Come and visit the Magstim team at our stand on the 28th & 29th of November to explore how our innovative TMS technology is supporting clinicians and improving patient outcomes. 💡 🧠 Whether you're interested in cost-effective transcranial magnetic stimulation (TMS), streamlined workflows, or our UK-based support services, we’re here to answer your questions and discuss how Magstim can enhance your practice. 📍 If you’re attending, we’d love to connect! Stop by for a chat with Derin Rose & Karen Wendt. #RoyalCollegeOfPsychiatrists #TMS #MentalHealthInnovation #Magstim #Neurotechnology

Watch now! Live TMS webinar for Magstim INSPIRE system workflow. The video recording from Nov 20 TMS webinar is now streaming on YouTube. THANK YOU to all who joined and for your great questions! This webinar shares the workflow for the Horizon Inspire, a new FDA-cleared Transcranial Magnetic Stimulation (TMS) for clinical treatment of MDD, OCD and decreasing Anxious Depression symptoms*. The Horizon Inspire is a next-generation, compact TMS system offering physicians, nurse practitioners and medical professions an easy to use, affordable system for effective treatments. Ideal for practices starting a new TMS treatments to support patient care to grow business revenue. * The Horizon Inspire is a configuration of the Horizon 3.0 TMS therapy system. The FDA has previously cleared the Magstim Horizon 3.0 TMS Therapy System for the treatment of depressive episodes for decreasing anxiety symptoms for those who may exhibit comorbid anxiety symptoms in adult patients suffering from Major Depressive Disorder (MDD) - also known as Anxious Depression. #TMS #depression #psychiatry #OCD Click here to watch: https://lnkd.in/gqDnHWYH Learn more at https://lnkd.in/gytY6t9w

Exciting New TMS Research: Transcranial direct current stimulation with repetitive transcranial magnetic stimulation effective for depression Study states: "Evidence Rating Level: 1 (Excellent) Noninvasive brain-stimulation techniques such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS) have each been found to be effective in treating depression when applied individually. However, it remains unclear whether the combination of rTMS and tDCS offers greater efficacy in treating major depressive disorder (MDD). This study thus examined the efficacy and safety of rTMS and tDCS, both individually and in combination, in patients with MDD. This double-blind, sham-controlled randomized clinical trial included adults aged 18-65 diagnosed with MDD from three hospitals in China." Study further states: "Overall, this study found that the combination of tDCS + rTMS was safe and had greater efficacy in reducing depressive symptoms in participants with MDD than tDCS + rTMS alone. Future studies are needed to confirm study findings and elucidate the mechanisms underlying the synergistic effect tDCS + rTMS." Study states: "We used a Magstim Rapid stimulator (Magstim Ltd) for the rTMS treatment, with all patients receiving 10-Hz stimulation via a figure-8 coil on the left DLPFC. Each session included 40 trains (1600 pulses) with 4-second intervals and 26-second intertrain breaks. Treatments were delivered at 110% resting motor threshold from Monday through Friday for 2 weeks. Sham stimulation treatments were performed using a pseudostimulation coil (Coil-D70air film; Magstim Ltd). This coil was placed on the left DLPFC and emitted only sound without stimulation." Thank you to Physician's Weekly for featuring this study published in JAMA Network Open #depression #tDCS #tms https://lnkd.in/gjg_XXJB

Friday TMS video inspiration from U.S. Department of Veterans Affairs team working to improve lives for veterans worldwide. The Magstim team was honored to work with the amazing VA video production team to share this technology. #TMS #depression #veterans #mentalhealth https://lnkd.in/guSbHjBM

Exciting New Product Launch Announcement! For over 30 years, Magstim has supported the UK NHS and UK Clinics with innovative solutions to improve patients’ mental health with non-invasive TMS Treatment. UK Product Launch date: 27th November 2024!   ✅ 30 Years NHS trusted supplier ✅ UK Manufactured ✅ UK Support and Service ✅ Committed to innovation   Keep up to date with Magstim and let us inspire you with the future of neuromodulation! www.magstim.com #Magstim #HorizonInspire #ProductLaunch #InnovationInHealthcare #Neuromodulation

New TMS research report and video: Targeted Magnetic Stimulation Slows Alzheimer's Progression in Phase II Study— Neuro-navigated repetitive TMS in the precuneus slowed progression in mild-to-moderate disease Thank you to MedPage Today for sharing this important research. Article states,"A personalized transcranial magnetic stimulation (TMS) protocol, designed to stimulate the precuneus within the default mode network, was well tolerated and significantly slowed clinical decline in patients with mild-to-moderate Alzheimer's disease, according to data presented at the Clinical Trials on Alzheimer's Disease (CTAD) annual meeting in Madrid." #TMS #Alzheimers #brain https://lnkd.in/gKhxytWC

LIVE TMS Webinar Wednesday. RSVP today to save your spot as few spaces remaining to learn patient workflow for new powerful portable cost effective Magstim INSPIRE TMS. 12 Noon EST Nov 20. click here to RSVP: https://lnkd.in/gncy4773 #depression #mentalhealth #nursepractitioner #psychiatry